Side Effects of tivozanib: A Synthesis of Findings from 7 Studies

  1. Home
  2. Side Effects of tivozanib
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of tivozanib: A Synthesis of Findings from 7 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of tivozanib: A Synthesis of Findings from 7 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Tivozanib is a potent pan-VEGF receptor tyrosine kinase inhibitor that has shown promise in treating advanced or metastatic renal cell carcinoma. 5 It demonstrates superior biological activity compared to other VEGF tyrosine kinase inhibitors. 5 In Phase I studies, the observed side effects were generally mild, with hypertension being the most common adverse event. 5 Further clinical trials are underway to evaluate the efficacy of tivozanib in combination with various cytotoxic drug regimens and other target-specific anticancer agents, such as mTOR inhibitors. 5 However, tivozanib has not yet been approved for regular use.

Reasons for Side Effects

Tivozanib works by inhibiting the function of VEGFR, which is essential for the formation and maintenance of blood vessels. This inhibition of blood vessel formation can lead to various side effects.

Common Side Effects

Hypertension

Hypertension is a common side effect of tivozanib, as reported in multiple studies. 5 3 2 This is likely due to the narrowing of blood vessels caused by the inhibition of blood vessel formation. 2 The severity of hypertension can vary depending on the dose and the individual patient's condition.

Fatigue

Fatigue is another common side effect associated with tivozanib. 3 4 It may be caused by insufficient oxygen supply due to the inhibition of blood vessel formation.

Other Side Effects

Other side effects reported in studies include:

  • Alopecia 4
  • Nausea 4
  • Diarrhea 4
  • Peripheral neuropathy 4
  • Neutropenia 4
  • Thyroid dysfunction 3

Side Effect Management

Hypertension

Antihypertensive medications can effectively manage hypertension associated with tivozanib. 5 The choice of antihypertensive medication will depend on the severity of hypertension and the patient's individual health status.

Other Side Effects

Side effects of tivozanib may vary depending on the dose and the individual's health condition. If you experience any side effects, consult your doctor for proper management strategies.

Comparison Across Studies

Commonalities

Multiple studies consistently demonstrate that tivozanib is a tyrosine kinase inhibitor targeting VEGFR 1, 2, and 3. 5 6 4 These studies also suggest that tivozanib could be an effective treatment option for patients with renal cell carcinoma. 5 6 However, tivozanib remains unapproved for regular use.

Differences

Variations exist in the methods of tivozanib administration, target patient groups, and evaluation criteria across these studies. As a result, direct comparisons of research findings might be challenging. However, the overall consensus from these studies suggests that tivozanib holds potential as an effective anti-cancer agent.

Notes on Real-World Applications

Tivozanib is currently in clinical trials and has not yet received approval for general use. Its safety and efficacy are still under investigation. If you are considering tivozanib treatment, closely follow your doctor's instructions and be aware of potential side effects.

Limitations of Current Research

Further research is required to fully evaluate the safety and efficacy of tivozanib, particularly regarding its long-term effects. The effectiveness of tivozanib for various types of cancer and its potential benefits when combined with other treatments also require further investigation.

Future Research Directions

Future research should focus on comprehensively assessing the safety and efficacy of tivozanib, including long-term effects, effectiveness in combination therapies, and its potential for treating a broader range of cancer types.

Conclusion

Tivozanib, a potent VEGF receptor tyrosine kinase inhibitor, shows promise in treating advanced or metastatic renal cell carcinoma. However, it's important to note that tivozanib is still under clinical investigation and not yet approved for regular use. Further research is essential to fully understand its safety, efficacy, and long-term effects. If you are considering tivozanib treatment, consult with your doctor and be aware of potential side effects.

Literature analysis of 7 papers
Positive Content
7
Neutral Content
0
Negative Content
0
Article Type
2
0
0
4
7
1.

Tivozanib, a highly potent and selective inhibitor of VEGF receptor tyrosine kinases, for the treatment of metastatic renal cell carcinoma.

Author: JacobAllen, ShookJaret, HutsonThomas E

Tumor shrinkage

This review examines the efficacy and safety of tivozanib, a novel, orally bioavailable VEGF tyrosine kinase inhibitor, in the treatment of advanced renal cell carcinoma. Tivozanib selectively targets VEGF receptors 1, 2, and 3, offering a potential advantage over broad-spectrum tyrosine kinase inhibitors by minimizing debilitating side effects.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

2.

Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma.

Author: Randrup HansenCaroline, GrimmDaniela, BauerJohann, WehlandMarkus, MagnussonNils E

mRCC treatment
Hypertension

Targeted therapies have revolutionized the treatment of metastatic renal cell carcinoma (mRCC), but the role of sorafenib and sunitinib remains important. This review discusses the current utility, adverse effects, and future directions for sorafenib, sunitinib, and newer targeted therapies in the management of mRCC.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

3.

Thyroid dysfunctions induced by tyrosine kinase inhibitors.

Author: FallahiPoupak, FerrariSilvia M, VitaRoberto, Di DomenicantonioAndrea, CorradoAlda, BenvengaSalvatore, AntonelliAlessandro

TKI anticancer therapy
Fatigue
Hypertension
Thyroid dysfunction

Tyrosine kinase inhibitors (TKIs) are a new class of anticancer therapy but can cause significant side effects, including fatigue, hypertension, and thyroid dysfunction.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

4.

A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer.

Author: MayerErica L, ScheulenM E, BeckmanJ, RichlyH, DuarteA, CotreauM M, StrahsA L, AgarwalS, SteelmanL, WinerE P, DicklerM N

Metastatic breast cancer treatment
Drug interactions
Toxicity

Tivozanib, a tyrosine kinase inhibitor, was found to be tolerable in combination with weekly paclitaxel in patients with metastatic breast cancer.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

5.

Structure, development, preclinical and clinical efficacy of tivozanib (KRN-951, AV-951).

Author: HaberkornBrigitte C M, EskensFerry A L M

Tumor regression
Hypertension

Tivozanib is a potent tyrosine kinase inhibitor that targets the VEGF receptor. It has shown promising results in clinical trials for patients with advanced renal cell carcinoma and is currently being investigated for other cancer types.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

6.

Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma.

Author: NosovDmitry A, EstevesBrooke, LipatovOleg N, LyulkoAlexei A, AnischenkoA A, ChackoRaju T, DovalDinesh C, StrahsAndrew, SlichenmyerWilliam J, BhargavaPankaj

Antitumor activity
Hypertension

This phase II, randomized discontinuation trial evaluated the antitumor activity and safety of tivozanib in patients with advanced/metastatic renal cell carcinoma (RCC). Tivozanib demonstrated objective response rates of 18% at 16 weeks and 24% overall. The median progression-free survival was 11.7 months. The most common grade 3 and 4 treatment-related adverse event was hypertension (12%).

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

7.

Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors.

Author: EskensFerry A L M, de JongeMaja J A, BhargavaPankaj, IsoeToshiyuki, CotreauMonette M, EstevesBrooke, HayashiKunihiko, BurgerHerman, ThomeerMaarten, van DoornLeni, VerweijJaap

Tumor reduction
Ataxia
Fatigue
Hypertension
Proteinuria
Transaminase elevation

This study assessed the maximum tolerated dose (MTD)/dose-limiting toxicities (DLT), safety, pharmacokinetics, and pharmacodynamics of tivozanib, a potent and selective oral VEGF receptor (VEGFR) tyrosine kinase inhibitor, in 41 patients with advanced solid tumors. The MTD was determined to be 1.5 mg/day. Tivozanib was well tolerated with manageable side effects, and encouraging and durable clinical activity was observed.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.